Arbutus Biopharma Corp Interest Expense Nonoperating
Arbutus Biopharma Corp (ABUS) reported Interest Expense Nonoperating of $18.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- Arbutus Biopharma Corp interest expense nonoperating for the quarter ending 2026-06-30 was $18.00K, a 35.71% decline year-over-year.
- Arbutus Biopharma Corp interest expense nonoperating for the quarter ending 2026-03-31 was $17.00K, a 39.29% decline year-over-year.
- Arbutus Biopharma Corp interest expense nonoperating for the quarter ending 2025-12-31 was $18.00K, a 40.00% decline year-over-year.
- Arbutus Biopharma Corp interest expense nonoperating for the quarter ending 2025-09-30 was $23.00K, a 20.69% decline year-over-year.
- Arbutus Biopharma Corp interest expense nonoperating for fiscal 2025 was $97.00K, a 29.20% decline from fiscal 2024.
- Arbutus Biopharma Corp interest expense nonoperating for fiscal 2024 was $137.00K, a 70.15% decline from fiscal 2023.
- Arbutus Biopharma Corp interest expense nonoperating for fiscal 2023 was $459.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.00K 10-Q · filed 2026-08-12 | $35.00K 10-Q · filed 2026-08-12 | $53.00K derived: sum of 3 quarters · filed 2026-08-12 | $76.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $17.00K 10-Q · filed 2026-05-13 | $35.00K derived: sum of 2 quarters · filed 2026-05-13 | $58.00K derived: sum of 3 quarters · filed 2026-05-13 | $86.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $41.00K derived: sum of 2 quarters · filed 2026-03-23 | $69.00K derived: sum of 3 quarters · filed 2026-08-12 | $97.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-13 | $51.00K derived: sum of 2 quarters · filed 2026-08-12 | $79.00K 10-Q · filed 2025-11-13 | $109.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $28.00K 10-Q · filed 2026-08-12 | $56.00K 10-Q · filed 2026-08-12 | $86.00K derived: sum of 3 quarters · filed 2026-08-12 | $115.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $28.00K 10-Q · filed 2026-05-13 | $58.00K derived: sum of 2 quarters · filed 2026-05-13 | $87.00K derived: sum of 3 quarters · filed 2026-05-13 | $121.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $59.00K derived: sum of 2 quarters · filed 2026-03-23 | $93.00K derived: sum of 3 quarters · filed 2026-03-23 | $137.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $29.00K 10-Q · filed 2025-11-13 | $63.00K derived: sum of 2 quarters · filed 2025-11-13 | $107.00K 10-Q · filed 2025-11-13 | $151.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $34.00K 10-Q · filed 2025-08-06 | $78.00K 10-Q · filed 2025-08-06 | $122.00K derived: sum of 3 quarters · filed 2025-08-06 | $168.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $44.00K 10-Q · filed 2025-05-14 | $88.00K derived: sum of 2 quarters · filed 2025-05-14 | $134.00K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $90.00K derived: sum of 2 quarters · filed 2025-03-27 | $459.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $46.00K 10-Q · filed 2024-11-06 | $415.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |